Curis, Inc. Analysts Trim Price Target After Q2 Report

Analysts have trimmed their Curis, Inc. (NASDAQ:CRIS) price target after its latest report, with revenues arriving 4.2% better than analyst forecasts at US$2.7m and statutory losses 4.2% smaller than expected. The analysts have upgraded their revenue forecasts and made a favorable reduction to loss per share. However, the consensus price target fell 22%, to US$16.33, suggesting that analysts remain pessimistic on the company despite the improved earnings and revenue outlook.

Curis Inc (NASDAQ:CRIS), a biotechnology company focused on innovative cancer therapeutics, has released its Q2 2025 earnings report. The company's revenues came in at $2.7 million, surpassing analyst forecasts by 4.2% [2]. The net loss, however, was $8.6 million, which was 4.2% lower than expected [2]. Despite these improvements, analysts have trimmed their price target, with the average estimate falling from $20.00 to $16.33, a 22% decrease [1].

The revenue for the second quarter of 2025 was $2.7 million, up 8% year-over-year, and the net loss was $8.6 million, down 27% year-over-year [2]. This marks a significant improvement in financial performance compared to the previous year. The company's revenue for the six months ended June 30, 2025, was $5.1 million, an 11% increase year-over-year, while the net loss for the same period was $19.2 million, a 19% decrease year-over-year [2].

Analysts have upgraded their revenue forecasts and reduced their loss per share estimates, indicating a more optimistic outlook on the company's financial performance. However, the consensus price target has fallen, suggesting that analysts remain cautious about the company's prospects despite the improved earnings and revenue outlook.

Curis Inc faces operational challenges, including the need for substantial additional funding to support its research and development program [2]. The company's strategic focus is on the development and commercialization of emavusertib, an orally available small molecule inhibitor of IRAK4, with multiple clinical trials ongoing [2].

The company's stock has experienced volatility, with analysts providing a range of price targets from $12.00 to $20.00, with an average target of $16.33, suggesting a potential upside of 908.23% from the current price of $1.62 [1].

References:
[1] https://finance.yahoo.com/news/curis-inc-cris-q2-2025-141316243.html
[2] https://www.tradingview.com/news/tradingview:c0a9f7ccdcefd:0-curis-inc-sec-10-q-report/